China NMPA Product Recall - Risperidone microspheres for injection

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, initiated a voluntary recall of a specific batch of its risperidone microspheres 25mg for injection in the United States. This significant action was taken due to a positive sterility test result for batch number 4212AAP1 (drug) and 309316 (packaging). The recall, publicly announced by the National Medical Products Administration (NMPA) on September 13, 2013, exclusively targeted the U.S. market, with Janssen confirming that no products distributed in China were affected. Despite the recall's limited geographical scope, the NMPA's involvement underscores a commitment to public health oversight. As the primary regulatory authority in China, the NMPA utilized this information to mandate specific actions within its jurisdiction. It formally requested that provincial, autonomous region, and municipal food and drug administrations strengthen their supervision and management of similar pharmaceutical products. This measure aims to proactively ensure the ongoing safety and quality of medications available in the Chinese market, even for products not directly involved in the foreign recall. The incident highlights the critical importance of sterility in injectable pharmaceuticals and the vigilance required from both manufacturers and regulatory bodies worldwide to maintain product integrity and patient safety.